Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Amplia Therapeutics Limited: Strengths and Weaknesses

Highlights: Amplia Therapeutics Limited
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses: Amplia Therapeutics Limited
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last few months, analysts have been revising downwards their earnings forecast.

Rating Financials

Amplia Therapeutics Limited SectorAustralia

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Amplia Therapeutics Limited SectorAustralia

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Amplia Therapeutics Limited SectorAustralia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Amplia Therapeutics Limited SectorAustralia

Visibility

-

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

-

Surprise rates

-

Rating Revisions

Amplia Therapeutics Limited SectorAustralia

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

-

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
56.45M - - - - -
73.45B
AAA
62.99B
A
28.05B -
A
- -
25.42B
AAA
23.3B - - - -
19.45B
A
18.16B
AA
16.53B -
AA
- -
13.16B
BB
Average 28.06B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ATX Stock
  4. Ratings Amplia Therapeutics Limited